UroStream

To live or to live well?” This Shakespearean dilemma continues to haunt many patients with bladder cancer. How to provide longer-lasting disease control while preserving the bladder through safer and more tolerable strategies has become a central challenge in urologic oncology. At the 2025 ASCO Annual Meeting, Professor Yijun Shen from Fudan University Shanghai Cancer Center presented the Phase II ReBirth study, which evaluates stratified bladder-sparing treatment strategies based on whether patients achieve clinical complete response (cCR) following neoadjuvant immunochemotherapy.

At the “CACA Integrated Prostate Oncology Conference” held from June 14–15, numerous Chinese experts and scholars gathered under the theme “Winning Through Integration in Cancer Control” to engage in academic discussions on the latest CACA prostate cancer guideline updates, recent research advances, and multidisciplinary team (MDT) evaluations of complex cases. Professor Dingwei Ye from Fudan University Shanghai Cancer Center delivered a keynote lecture titled “The Three Dimensions of Surgical Treatment for Prostate Cancer — Skill Advancement, Technological Innovation, and Conceptual Reform.” The following is a summary of his presentation.

Editor’s Note: Upper tract urothelial carcinoma (UTUC), which originates in the renal pelvis or ureter, is a distinct disease entity with unique characteristics in China. Accounting for 17.9% of all…

The 2025 Annual Meeting of the Chinese Urological Association (CUDA), held from June 12 to 15 in the romantic city of Zhuhai, brought together leading experts under the theme “Healthy China, Urology First.” At the conference, Professor Jiwei Huang from Renji Hospital, Shanghai Jiao Tong University School of Medicine, delivered a compelling presentation on neoadjuvant therapy for upper tract urothelial carcinoma (UTUC). In an exclusive interview with Oncology Frontier – UroStream, he further discussed his team’s research and practical experience in this evolving field.

At the forefront of surgical innovation, Dr. Qu Fajun (Changzheng Hospital) presented a refined interpretation of the Hood technique using a cutting-edge single-port robotic platform. Aiming to elevate prostate cancer…

At the Pujiang Prostate Cancer Academic Conference, Dr. Kan Gong (Peking University First Hospital) introduced an AI-driven diagnostic workflow that enhances prostate cancer precision care—from refined PSAD calculation to advanced…